Degree of stemness predicts micro-environmental response and clinical outcomes of diffuse large B-cell lymphoma and identifies a potential targeted therapy

• Published in: Frontiers in immunology Vol. 13; p. 1012242
• Main Authors: Hu, Fang, Li, Huan, Li, Lei, Gale, Robert Peter, Song, Yuanbin, Chen, Shuiqin, Liang, Yang
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 08.11.2022
• Subjects: dequalinium chloride; diffuse large B-cell lymphoma; Immunology; single-sample gene set enrichment analysis; stem cells; targeted therapy; weighted gene co-expression network analysis
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.1012242

Some cells within a diffuse large B-cell lymphoma (DLBCL) have the genotype of a stem cell, the proportion of which is termed degree of stemness . We interrogated correlations between the degree of stemness with immune and stromal cell scores and clinical outcomes in persons with DLBCL. We evaluated gene expression data on 1,398 subjects from Gene Expression Omnibus to calculate the degree of stemness . Subjects were classified into low- and high-stemness cohorts based on restricted cubic spline plots. Weighted gene co-expression network analysis (WGCNA) was used to screen for stemness-related genes. Immune and stromal scores correlated with the degree of stemness (both P < 0.001). A high degree of stemness correlated with a shorter progression-free survival (PFS; Hazard Ratio [HR; 95% Confidence Interval [CI] =1.90 (1.37, 2.64; P < 0.001) and a shorter survival (HR = 2.29 (1.53, 3.44; P < 0.001). CDC7 expression correlated with the degree of stemness , and CDC7-inhibitors significantly increased apoptosis ( P < 0.01), the proportion of cells in G 1 phase ( P < 0.01), and inhibited lymphoma growth in a mice xenograft model ( P = 0.04). Our data indicate correlations between the degree of stemness , immune and stromal scores, PFS, and survival. These data will improve the prediction of therapy outcomes in DLBCL and suggest potential new therapies.